Natixis Advisors LLC Acquires 335,667 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Natixis Advisors LLC lifted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 198.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 504,534 shares of the company's stock after buying an additional 335,667 shares during the period. Natixis Advisors LLC's holdings in Teva Pharmaceutical Industries were worth $11,120,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Smithfield Trust Co increased its holdings in Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after purchasing an additional 980 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at about $50,000. Ameliora Wealth Management Ltd. purchased a new position in Teva Pharmaceutical Industries during the 4th quarter valued at about $66,000. IFP Advisors Inc increased its holdings in Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after purchasing an additional 1,960 shares during the period. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in Teva Pharmaceutical Industries during the 4th quarter valued at about $104,000. Hedge funds and other institutional investors own 54.05% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. UBS Group reduced their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Bank of America reduced their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday. Finally, Barclays reduced their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $23.43.

Remove Ads

Teva Pharmaceutical Industries Stock Down 0.4 %

Shares of TEVA traded down $0.07 during mid-day trading on Friday, reaching $16.18. The company had a trading volume of 9,419,423 shares, compared to its average volume of 9,442,554. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm has a 50-day moving average price of $17.79 and a 200 day moving average price of $18.21. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80. The company has a market capitalization of $18.34 billion, a price-to-earnings ratio of -11.16, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.